<?xml version="1.0"?>
<?xml-stylesheet type="text/css" href="http://www.feuxdelamour.com/v4/skins/common/feed.css?303"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="fr">
		<id>http://www.feuxdelamour.com/v4/index.php?action=history&amp;feed=atom&amp;title=2_Invaluable_Compounds_For_The_MRIP</id>
		<title>2 Invaluable Compounds For The MRIP - Historique des versions</title>
		<link rel="self" type="application/atom+xml" href="http://www.feuxdelamour.com/v4/index.php?action=history&amp;feed=atom&amp;title=2_Invaluable_Compounds_For_The_MRIP"/>
		<link rel="alternate" type="text/html" href="http://www.feuxdelamour.com/v4/index.php?title=2_Invaluable_Compounds_For_The_MRIP&amp;action=history"/>
		<updated>2026-05-17T02:48:58Z</updated>
		<subtitle>Historique pour cette page sur le wiki</subtitle>
		<generator>MediaWiki 1.20alpha</generator>

	<entry>
		<id>http://www.feuxdelamour.com/v4/index.php?title=2_Invaluable_Compounds_For_The_MRIP&amp;diff=95769&amp;oldid=prev</id>
		<title>Angle3oil : Page créée avec « Consistently, sirolimus has been shown to impair murine myocyte respiration [3]. Inhibition of mTOR also has been shown to activate AMP-activated protein kinase (catalyzes... »</title>
		<link rel="alternate" type="text/html" href="http://www.feuxdelamour.com/v4/index.php?title=2_Invaluable_Compounds_For_The_MRIP&amp;diff=95769&amp;oldid=prev"/>
				<updated>2017-04-30T11:10:22Z</updated>
		
		<summary type="html">&lt;p&gt;Page créée avec « Consistently, sirolimus has been shown to impair murine myocyte respiration [3]. Inhibition of mTOR also has been shown to activate AMP-activated protein kinase (catalyzes... »&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Nouvelle page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Consistently, sirolimus has been shown to impair murine myocyte respiration [3]. Inhibition of mTOR also has been shown to activate AMP-activated protein kinase (catalyzes the reaction: AMP + ATP �� 2ADP), [http://www.selleckchem.com/products/PD-173074.html FGFR inhibitor] resulting in improved cellular ?bioenergetics (��substrate-level phosphorylation and ��oxidative phosphorylation) [4]. The results here demonstrate that inhibition of cellular respiration dominates the sirolimus biologic effects, perhaps due to the high drug concentration (10 ��M) used in this study. It is worth noting, however, that the 10 ��M dose was employed in order to elicit the cellular response at a relatively brief exposure (about one hour). Due to this experimental limitations, it is unclear whether concentrations [http://en.wikipedia.org/wiki/MRIP MRIP] and the previously described dual PI3K/mTOR inhibitors GSK2126458, BEZ235, and GDC0980 [12], support the use of cellular respiration as a surrogate biomarker for monitoring drugs targeting mTOR. In contrast, other molecularly targeted agents, such as GSK1120212 (MEK inhibitor), sorafenib/regorafenib (multikinase inhibitors) [12], and tacrolimus/cyclosporine (calcineurin inhibitor; Tables 1 and ?and2)2) have no or minimum effects on cellular respiration. Thus, cellular respiration is shown in this study to differentiate between distinct molecularly targeted classes (mTOR inhibition �� ��cellular respiration). The mitochondria use energy derived from oxidations in the respiratory chain to produce ATP (oxidative phosphorylation). These vital [http://www.selleckchem.com/products/Temsirolimus.html selleck compound] organelles also are responsible for releasing pro-apoptotic molecules that trigger the caspase cascade [19]. Caspase activation causes mitochondrial dysfunction [19]. In conclusion, the results show the mTOR inhibitor sirolimus impairs cellular respiration in vital organs (Table 1) [12]. Inhibitors of the calcium-dependent serine-threonine phosphatase (tacrolimus and cyclosporine) have no or minimum effects on cellular respiration (Tables 2 and ?and3).3). Cellular bioenergetics is a useful biomarker for compounds that target mTOR signals [20]. Acknowledgements This research was supported by a grant from the UAE University, NRF (31M096). Disclosure of conflict of interest The authors declare no conflict of interest.&lt;/div&gt;</summary>
		<author><name>Angle3oil</name></author>	</entry>

	</feed>